On July 23 and 24, 2026, FDA's Pharmacy Compounding Advisory Committee (PCAC) recommended six of seven peptides for the 503A compounding list, over the objections of the agency's own review staff. It was the most-covered event in this market in years.
Four weeks on, it has left no mark on what these compounds cost.
What was compared
Prices are compared listing against listing, between the week of July 9-15, 2026 and the week of August 5-11, 2026, with the vote falling between them. A listing counts only if it was in stock and priced in both weeks. Full definitions are on the methodology page.
Five of the six recommended peptides are carried widely enough to measure: BPC-157, KPV, MOTS-c, Semax and Epitalon. The sixth, TB-500, is a special case covered further down.
The recommended peptides moved with the market, not ahead of it
- On the five measurable peptides: 133 matched listings from 22 vendors, of which 22.6% changed price. The median change was zero.
- On the other 71 compounds in the index: 849 matched listings from 22 vendors, of which 24.1% changed price. The median change was also zero.
Among listings that did move, roughly three rose for every one that fell, in both groups alike. A favorable federal recommendation produced a repricing rate a percentage point and a half below the market it sits in.
Median listed prices for the five, as of August 11, 2026:
- BPC-157: $4.67 per milligram, across 42 in-stock listings from 24 vendors.
- KPV: $4.20 per milligram, across 24 in-stock listings from 20 vendors.
- MOTS-c: $3.55 per milligram, across 47 in-stock listings from 24 vendors.
- Semax: $4.00 per milligram, across 25 in-stock listings from 20 vendors.
- Epitalon: $3.00 per milligram, across 27 in-stock listings from 22 vendors.
The peptide the panel rejected behaved the same way
The committee voted against one of the seven: emideltide, sold in this market as DSIP. It failed by a single vote. If a favorable recommendation were moving prices, the compound that did not get one is where the difference should appear.
It does not appear. Across 24 matched listings from 18 vendors, DSIP repriced at 20.8% with a median change of zero, the same band as the five peptides the panel backed and the same band as everything else. As of August 11, 2026 its median listed price is $5.80 per milligram, higher than any of the five recommended compounds.
In the price data, recommendation and rejection are indistinguishable.
For one of the six, there is almost nothing to move
The substance the committee recommended as "TB-500" is the seven-residue fragment thymosin beta-4 17-23. The molecule the research market sells under that name is full-length thymosin beta-4, a different compound with a different registry number.
One vendor in this index lists the fragment the panel voted on, at $4.80 per milligram. Twenty-three list the full-length protein, at a median of $5.50 per milligram, as of August 11, 2026. For that nomination, a favorable rule would reach a single listed product.
Why this is the expected result
A PCAC vote is advisory. The 503A list is set through notice-and-comment rulemaking, so FDA must still propose a rule, take comment, and issue a final rule before any of these substances is lawfully compoundable. As of August 11, 2026 it has not begun: the Federal Register carries no FDA document on the 503A bulk drug substances list since the meeting.
The second reason is more durable. A 503A rule governs what a licensed compounding pharmacy may prepare against a prescription, for the specific indication each nomination named. It does not reach material sold for research use, which is what every price in this report describes. The two channels would not be the same market, and a rule in one is not a supply or demand event in the other.
Sticky prices are also the normal condition here rather than a reaction to anything. Across the three monthly issues of our price index, between 76% and 88% of matched listings ended each month at exactly the price they started it.
What would show up in the data
If FDA opens rulemaking on the six, that is the first moment with a plausible mechanism behind it. A proposed rule creates prescribers, pharmacies and telehealth platforms with a commercial stake in these compounds, and that is a demand story the research channel would feel. Nothing before then has one.
We publish a monthly price index and will report a move on these compounds if one arrives.
What this does not measure
- It measures listed prices, not transaction prices. Coupons, first-order discounts and bulk terms are not applied.
- It does not test products, verify purity, or assess any vendor's certificates of analysis.
- Vendor and listing counts describe what this index covers, not the size of the market.
Sources
- FDA, July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee
- FDA, Bulk Drug Substances Used in Compounding Under Section 503A
- Federal Register: FDA compounding documents, checked August 11, 2026 for any rulemaking following the vote.
- What the FDA peptide compounding vote does and does not change: the vote tallies, the per-compound indications, and the TB-500 identity problem.
- PeptideScouter methodology: index construction, normalization and known limits.
- PeptideScouter price index: the live per-milligram figures this report is drawn from.
All figures in this report are as of August 11, 2026, computed from PeptideScouter's own daily price archive.